AU2023240827A1 - Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression - Google Patents

Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression Download PDF

Info

Publication number
AU2023240827A1
AU2023240827A1 AU2023240827A AU2023240827A AU2023240827A1 AU 2023240827 A1 AU2023240827 A1 AU 2023240827A1 AU 2023240827 A AU2023240827 A AU 2023240827A AU 2023240827 A AU2023240827 A AU 2023240827A AU 2023240827 A1 AU2023240827 A1 AU 2023240827A1
Authority
AU
Australia
Prior art keywords
ires
plasmid vector
orf
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023240827A
Other languages
English (en)
Inventor
Suradej HONGENG
Patompon WONGTRAKOONGATE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Adventure Co Ltd
Mahidol University
Original Assignee
Bio Adventure Co Ltd
Office Of National Higher Education Science Res And Innovation Policy Council
Mahidol University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Adventure Co Ltd, Office Of National Higher Education Science Res And Innovation Policy Council, Mahidol University filed Critical Bio Adventure Co Ltd
Publication of AU2023240827A1 publication Critical patent/AU2023240827A1/en
Assigned to MAHIDOL UNIVERSITY, BIO ADVENTURE CO., LTD. reassignment MAHIDOL UNIVERSITY Request for Assignment Assignors: BIO ADVENTURE CO., LTD., MAHIDOL UNIVERSITY, OFFICE OF NATIONAL HIGHER EDUCATION SCIENCE RESEARCH AND INNOVATION POLICY COUNCIL
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2023240827A 2022-03-21 2023-03-21 Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression Pending AU2023240827A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TH2201001686 2022-03-21
TH2201001686 2022-03-21
PCT/TH2023/000003 WO2023182948A1 (en) 2022-03-21 2023-03-21 Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression

Publications (1)

Publication Number Publication Date
AU2023240827A1 true AU2023240827A1 (en) 2024-07-18

Family

ID=86054332

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023240827A Pending AU2023240827A1 (en) 2022-03-21 2023-03-21 Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression

Country Status (6)

Country Link
US (1) US20250243507A1 (https=)
EP (1) EP4496598A1 (https=)
JP (1) JP2025509106A (https=)
CN (1) CN118871134A (https=)
AU (1) AU2023240827A1 (https=)
WO (1) WO2023182948A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024234874A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026006644A1 (en) * 2024-06-26 2026-01-02 Emervax, Inc. Circular mrna yellow fever vaccine
WO2026006593A1 (en) 2024-06-28 2026-01-02 Orna Therapeutics, Inc. Synthetic internal ribosome entry sites
CN119464284B (zh) * 2024-09-29 2026-02-13 复旦大学附属肿瘤医院 一种用于免疫细胞高效蛋白表达的环形rna疫苗平台及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2996697B1 (en) 2013-05-15 2019-06-26 Robert Kruse Intracellular translation of circular rna
CN112399860B (zh) 2018-06-06 2024-08-16 麻省理工学院 用于在真核细胞中翻译的环状rna
BR112021023411A2 (pt) 2019-05-22 2022-02-01 Massachusetts Inst Technology Composições e métodos de rna circular
CN114981409A (zh) * 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
JP7851254B2 (ja) * 2020-03-20 2026-04-24 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
AU2021269137A1 (en) * 2020-05-08 2022-12-15 Orna Therapeutics, Inc. Circular RNA compositions and methods
WO2021236855A1 (en) * 2020-05-19 2021-11-25 Orna Therapeutics, Inc. Circular rna compositions and methods
IL298362A (en) * 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Coronavirus antigen compositions and their uses
AU2021300378A1 (en) * 2020-07-01 2023-01-19 Elevatebio Technologies, Inc. Compositions and methods for cellular reprogramming using circular RNA
US20230346921A1 (en) * 2020-08-21 2023-11-02 Peking University Circular rna vaccines and methods of use thereof
AU2021336976A1 (en) * 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
BR112023023642A2 (pt) * 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
CN115404240A (zh) * 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
TW202317767A (zh) * 2021-06-10 2023-05-01 美商歐納醫療公司 環狀rna組合物及方法
CN115702940A (zh) * 2021-08-05 2023-02-17 苏州科锐迈德生物医药科技有限公司 包含环状rna分子的制剂在制备治疗肿瘤的药物中的应用

Also Published As

Publication number Publication date
EP4496598A1 (en) 2025-01-29
JP2025509106A (ja) 2025-04-11
US20250243507A1 (en) 2025-07-31
CN118871134A (zh) 2024-10-29
WO2023182948A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US20250243507A1 (en) Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression
US12331290B2 (en) Recombinant nucleic acid molecule and application thereof in preparation of circular RNA
AU2019280583B2 (en) Circular RNA for translation in eukaryotic cells
US11046975B2 (en) Bicistronic expression vector for antibody expression and method for producing antibody using same
Yu et al. Optimized circular RNA vaccines for superior cancer immunotherapy
CN111821433A (zh) mRNA疫苗及其合成方法、试剂盒
US20240091343A1 (en) Technology platform of uncapped-linear mrna with unmodified uridine
EP4349990A1 (en) Artificial polynucleotides for expressing proteins
US20200024365A1 (en) mRNA-ENCODED NANOBODY AND APPLICATION THEREOF
WO2023227124A1 (zh) 一种构建mRNA体外转录模板的骨架
CN117205309B (zh) 一种流感免疫原组合物和制备方法及其用途
CN114807154A (zh) 一种修饰的核酸及其应用
CN119177239A (zh) 一种编码胶原蛋白的核酸组合物
HK40116935A (zh) 用於增强蛋白质表达的内部核糖体进入位点(ires)、质粒载体和环状mrna
Oh et al. Loop structure in poly (A) tail of mRNA vaccine enhances antigen translation efficiency and mRNA stability
Liu et al. Development and application of an uncapped mRNA platform
CN112725378A (zh) 一种人工改造的akt3环状rna及其在新冠疫苗中的应用
KR102918706B1 (ko) mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
US20260125673A1 (en) Artificial polynucleotides for expressing proteins
CN120700010B (zh) 提高mRNA稳定性和翻译效率的UTR序列及其应用
HK40077179B (zh) 一种修饰的核酸及其应用
CN115232826B (zh) 一种基于1096骨架序列的新冠病毒疫苗
US12551451B2 (en) Compositions and methods for delivering molecules
Kumar et al. PCR-generated DNA templates enable efficient, rapid, and cost-effective mRNA synthesis
HK40077179A (en) Modified nucleic acid and use thereof